logo

Catabasis Pharmaceuticals, Inc. (CATB)



Trade CATB now with
  Date
  Headline
9/8/2021 8:18:18 AM Catabasis Pharmaceuticals Changes Name To Astria Therapeutics, Inc
1/29/2021 8:04:26 AM Catabasis Acquires Quellis Biosciences
9/28/2020 8:11:47 AM Catabasis Pharma Presents Information On Edasalonexent Program In Phase 3 Development For Duchenne Muscular Dystrophy
9/21/2020 8:09:49 AM Catabasis Promotes Noah Clauser To CFO
6/12/2020 8:04:13 AM Catabasis Names Ben Harshbarger As SVP, General Counsel
3/10/2020 8:09:08 AM Catabasis Pharma Q4 Net Loss $6.6 Mln Or $0.55/Shr Vs Loss Of $6.1 Mln Or $0.85/Shr Last Year
1/8/2020 8:12:59 AM Catabasis, Duchenne UK Partner To Evaluate Edasalonexent In Phase 2 Non-Ambulatory Duchenne Muscular Dystrophy Trial
7/29/2019 7:20:36 AM Wedbush Reiterates Catabasis Pharmaceuticals, Inc. (CATB) At Outperform With $18 Price Target
6/24/2019 10:03:28 AM Wedbush Reiterates Catabasis Pharmaceuticals, Inc. (CATB) At Outperform With $18 Price Target
3/20/2018 6:27:28 AM Wedbush Is Increasing Catabasis Pharmaceuticals, Inc. (CATB) FY18 Estimate To -0.91 From -1.00
3/20/2018 6:27:11 AM Wedbush Is Raising Catabasis Pharmaceuticals, Inc. (CATB) Q4 18 Estimate To -0.22 From -0.27